CANF Stock Analysis: Buy, Sell, or Hold?
CANF - Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares
$2.18
-0.03 (-1.27%)
▼
5d:
+0.93%
30d:
-7.54%
90d:
-42.58%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Apr 13, 2026
0d
Get Alerted When CANF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CANF shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CANF shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CANF is currently trading at $2.18, which is considered slightly low relative to its 30-day fair value range of $2.01 to $2.86.
Technical Outlook: Technically, CANF is in a downtrend. The price is currently testing key support at $2.14. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CANF scores 80/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.00 (+266.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CANF is in a downtrend. The price is currently testing key support at $2.14. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CANF scores 80/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.00 (+266.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.01 -
$2.86
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (80/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 266.6% below Wall St target ($8.00)
- CAUTION: Bottoming setup, but lagging the sector by 21% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$2.01 -
$2.86
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.14
Resistance Level
$2.28
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.40
Wall Street Target
$8.00
(+266.6%)
Share & Embed Analysis
Last updated: October 04, 2026 4:37 AM ET
Data refreshes hourly during market hours. Next update: 5:37 AM
Data refreshes hourly during market hours. Next update: 5:37 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CANF showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
